Ldlr - low density lipoprotein receptor Gene

Mus musculus

Also known as Hlb301

Gene ID: 16835 | Gene type: protein coding

About Ldlr

Summary

Enables several functions, including amyloid-beta binding activity; low-density lipoprotein particle binding activity; and low-density lipoprotein particle receptor activity. Involved in several processes, including lipid transport; regulation of inflammatory response; and regulation of lipid metabolic process. Acts upstream of or within several processes, including Cholesterol homeostasis; lipoprotein catabolic process; and low-density lipoprotein particle clearance. Located in several cellular components, including basolateral plasma membrane; endosome; and lysosome. Is expressed in several structures, including alimentary system; genitourinary system; musculoskeletal system; paravertebral ganglion; and sensory organ. Used to study familial hypercholesterolemia and fatty liver disease. Human ortholog(s) of this gene implicated in Alzheimer's disease; arteriosclerosis; familial hypercholesterolemia; hepatitis C; and migraine without aura. Orthologous to human LDLR (low density lipoprotein receptor). [provided by Alliance of Genome Resources, Apr 2022]

Ldlr Products(3)

mRNA	Protein	Name
NM_001252658.1	NP_001239587.1	low-density lipoprotein receptor isoform 2 precursor
NM_001252659.1	NP_001239588.1	low-density lipoprotein receptor isoform 3 presursor precursor
NM_010700.3	NP_034830.2	low-density lipoprotein receptor isoform 1 precursor

Gene Ontology

Molecular Function
Biological Process
Cellular Component

Molecular Function GO Annotation	Evidence	Reference	Source
enables amyloid-beta binding	IPI IPI: Inferred from physical interaction	22383525	MGI
enables low-density lipoprotein particle binding	IDA IDA: Inferred from direct assay	7848292	MGI
enables low-density lipoprotein particle receptor activity	IDA IDA: Inferred from direct assay	12072432	MGI
enables low-density lipoprotein particle receptor activity	IMP IMP: Inferred from mutant phenotype	17148552	MGI
enables protein binding	IPI IPI: Inferred from physical interaction	12169628	MGI
enables very-low-density lipoprotein particle receptor activity	IDA IDA: Inferred from direct assay	16166565	MGI

Biological Process GO Annotation	Evidence	Reference	Source
involved in amyloid-beta clearance	IGI IGI: Inferred from genetic interaction	20005821	MGI
involved in amyloid-beta clearance by cellular catabolic process	IDA IDA: Inferred from direct assay	22383525	MGI
involved in artery morphogenesis	IMP IMP: Inferred from mutant phenotype	22927332	MGI
involved in cellular response to fatty acid	IGI IGI: Inferred from genetic interaction	24255059	MGI
acts upstream of or within cholesterol homeostasis	IGI IGI: Inferred from genetic interaction	11120757	MGI
involved in cholesterol homeostasis	IGI IGI: Inferred from genetic interaction	25524771	MGI
acts upstream of or within cholesterol homeostasis	IMP IMP: Inferred from mutant phenotype	9788969	MGI
involved in cholesterol import	IMP IMP: Inferred from mutant phenotype	18175806	MGI
acts upstream of or within cholesterol metabolic process	IMP IMP: Inferred from mutant phenotype	17071966	MGI
acts upstream of or within cholesterol transport	IMP IMP: Inferred from mutant phenotype	17148552	MGI
acts upstream of or within establishment of localization in cell	IMP IMP: Inferred from mutant phenotype	17148552	MGI
involved in high-density lipoprotein particle clearance	IGI IGI: Inferred from genetic interaction	25524771	MGI
acts upstream of or within lipid metabolic process	IGI IGI: Inferred from genetic interaction	11120757	MGI
acts upstream of or within lipoprotein catabolic process	IDA IDA: Inferred from direct assay	15741654	MGI
acts upstream of or within lipoprotein catabolic process	IMP IMP: Inferred from mutant phenotype	9788969	MGI
acts upstream of or within lipoprotein metabolic process	IGI IGI: Inferred from genetic interaction	11120757	MGI
involved in long-term memory	IGI IGI: Inferred from genetic interaction	24412220	MGI
acts upstream of or within low-density lipoprotein particle clearance	IDA IDA: Inferred from direct assay	26965651	MGI
involved in low-density lipoprotein particle clearance	IMP IMP: Inferred from mutant phenotype	18175806	MGI
involved in negative regulation of amyloid fibril formation	IGI IGI: Inferred from genetic interaction	20005821	MGI
involved in negative regulation of astrocyte activation	IGI IGI: Inferred from genetic interaction	20005821	MGI
involved in negative regulation of gene expression	IMP IMP: Inferred from mutant phenotype	24255059	MGI
involved in negative regulation of microglial cell activation	IGI IGI: Inferred from genetic interaction	20005821	MGI
involved in negative regulation of protein metabolic process	IDA IDA: Inferred from direct assay	22383525	MGI
involved in phagocytosis	IDA IDA: Inferred from direct assay	22383525	MGI
involved in phospholipid transport	IMP IMP: Inferred from mutant phenotype	18175806	MGI
involved in plasma lipoprotein particle clearance	IDA IDA: Inferred from direct assay	22383525	MGI
involved in positive regulation of gene expression	IGI IGI: Inferred from genetic interaction	24255059	MGI
involved in positive regulation of gene expression	IMP IMP: Inferred from mutant phenotype	24255059	MGI
involved in positive regulation of inflammatory response	IGI IGI: Inferred from genetic interaction	24255059	MGI
involved in positive regulation of lysosomal protein catabolic process	IDA IDA: Inferred from direct assay	22383525	MGI
involved in positive regulation of triglyceride biosynthetic process	IMP IMP: Inferred from mutant phenotype	18175806	MGI
involved in receptor-mediated endocytosis	IDA IDA: Inferred from direct assay	20005821	MGI
involved in regulation of cholesterol metabolic process	IGI IGI: Inferred from genetic interaction	24412220	MGI
involved in regulation of phosphatidylcholine catabolic process	IMP IMP: Inferred from mutant phenotype	18175806	MGI
involved in regulation of protein metabolic process	IGI IGI: Inferred from genetic interaction	24412220	MGI
involved in response to caloric restriction	IGI IGI: Inferred from genetic interaction	24412220	MGI

Cellular Component GO Annotation	Evidence	Reference	Source
located in apical part of cell	IDA IDA: Inferred from direct assay	22848640	MGI
located in basolateral plasma membrane	IDA IDA: Inferred from direct assay	22848640	MGI
located in cell surface	IDA IDA: Inferred from direct assay	22848640	MGI
located in early endosome	IDA IDA: Inferred from direct assay	11092755	MGI
located in endosome	IDA IDA: Inferred from direct assay	12746448	MGI
located in late endosome	IDA IDA: Inferred from direct assay	11092755	MGI
located in lysosome	IDA IDA: Inferred from direct assay	11092755	MGI
located in plasma membrane	IDA IDA: Inferred from direct assay	20005821	MGI
located in somatodendritic compartment	IDA IDA: Inferred from direct assay	18341993	MGI
located in sorting endosome	IDA IDA: Inferred from direct assay	11092755	MGI

EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Protein Preferred Names

Protein Names

low-density lipoprotein receptor

LDL receptor

Recombinant Ldlr Proteins

Cat. No.	Product Name	Accession	Purity
HY-P73272	LDLR Protein, Mouse (HEK293, His)	P35951 (A22-R790)	≥95%
HY-P73838	LDLR Protein, Mouse (Biotinylated, A23V, C27G, HEK293, His)	P35951/NP_034830.2 (A22-R790, A23V, C27G)	≥95%

Related Agents

Approval

Bioactive Molecules (1)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-106539	Colesevelam hydrochloride		98.00%	Unkown

Clinical Phase

Bioactive Molecules (5)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P4073	ANG1005		98.83%	Phase 3
HY-152857	Muvalaplin	Inhibitor	99.96%	Phase 2
HY-109567	Gemcabene	Inhibitor	99.91%	Phase 2
HY-109567A	Gemcabene calcium	Inhibitor	≥98.0%	Phase 2
HY-116175	BIBB 515		99.44%	Phase 1

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Phase
HY-P99822	Recaticimab		99.71%	Phase 3
HY-P99793	Orticumab	Inhibitor	≥99.0%	Phase 2

Pre-clinical Phase

Bioactive Molecules (29)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P2341	Angiopep-2 hydrochloride		99.74%	Unkown
HY-NP013	Oxidized low density lipoprotein (mouse)		≥98.0%	Unkown
HY-145001	20-HC-Me-Pyrrolidine	Inhibitor	99.69%	Unkown
HY-101529	Imanixil		99.03%	Unkown
HY-125544	LY 295427	Modulator	≥98.0%	Unkown
HY-120651	LDL-IN-2	Inhibitor	≥99.0%	Unkown
HY-NP012	Low density lipoprotein (human)		/	Unkown
HY-A0127	Etofibrate	Activator	99.24%	Unkown
HY-100144	Pirozadil		98.31%	Unkown
HY-W015600	2-Acetamidophenol	Inhibitor	99.48%	Unkown
HY-U00054	LDL-IN-3	Inhibitor	/	Unkown
HY-147279	Milpocitide		/	Unkown
HY-167873	Habenariol	Inhibitor	/	Unkown
HY-115914	Lipid-lowering agent-1		/	Unkown
HY-P10698	VH-N412		/	Unkown
HY-P10697	VH4127	Modulator	/	Unkown
HY-161941	MeIm		/	Unkown
HY-P10911	IETP2	Ligand	/	Unkown
HY-P10502	L57		/	Unkown
HY-167870	Piceatannol 4'-O-glucoside	Inhibitor	/	Unkown
HY-113288	Campestanol	Inhibitor	≥99.0%	Unkown
HY-W423578	LDLR regulator-1	Modulator	/	Unkown
HY-126551	Butenoyl-PAF		/	Unkown
HY-164412	Phosphatidylcholine (C18:2,C20:4)	Activator	/	Unkown
HY-165512	Nicanartine	Inhibitor	/	Unkown
HY-123260	S12340	Inhibitor	/	Unkown
HY-138089	17β-Hydroxy exemestane	Inhibitor	/	Unkown
HY-159595	PCSK9-IN-29	Inducer	99.44%	Unkown
HY-161938	BRD8518		/	Unkown

Inhibitory Antibodies (2)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-P990143	Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6)	Inhibitor	95.00%	Unkown
HY-P990480	Anti-oxLDL Antibody		/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Ldlr	NCBI	NCBI:3949
Macaca fascicularis	Ldlr	NCBI	NCBI:102127361

Name
Email *

	Sorry, but the email address you supplied was invalid.